European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria

被引:133
|
作者
Valentini, G
Bencivelli, W
Bombardieri, S
D'Angelo, S
Della Rossa, A
Silman, AJ
Black, CM
Czirjak, L
Nielsen, H
Vlachoyiannopoulos, PG
机构
[1] Univ Naples 2, Naples, Italy
[2] Univ Pisa, Dept Internal Med, Clin Immunol Unit, I-56100 Pisa, Italy
[3] Univ Pisa, Dept Internal Med, Rheumatol Unit, I-56100 Pisa, Italy
[4] Univ Manchester, Manchester M13 9PL, Lancs, England
[5] Royal Free Hosp, London NW3 2QG, England
[6] Univ Pecs, Pecs, Hungary
[7] Herlev Hosp, Rheumatol Unit, Herlev, Denmark
[8] Natl Tech Univ Athens, Athens, Greece
关键词
D O I
10.1136/ard.62.9.901
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To further assess the construct validity of the three European Scleroderma Study Group (EScSG) preliminary activity indices for systemic sclerosis (SSc): for SSc as a whole, for diffuse SSc (dcSSc), and for limited SSc (lcSSc). Methods: 30/290 SSc clinical charts collected for the EScSG study used to develop activity criteria for SSc were selected and sent to four clinical experts in SSc. The experts ranked the charts from 1 to 30 (1=lowest activity, 30=highest activity). The relationships among the ranks given by each investigator and each of the three scores, and between any two of the ranks were investigated. Results: A consistently significant correlation (r(s)=0.530-0.712) was found between the ranks given by each of the four investigators and the index for the entire patient group. A similar level of agreement was detected between each couple of the four experts (r(s)=0.428-0.720). Moreover, the ranks given in patients with an index>3 were significantly higher than those given for patients with an indexless than or equal to3. This cut off point had previously been shown to best discriminate patients with active disease. Conclusions: Of the originally developed activity indexes, the whole series index has been externally validated. The index comprises the first preliminary, but necessary, groundwork to improve the concept of disease activity in SSc, which is still ill defined. It can be used as a preliminary activity index in clinical investigational studies.
引用
收藏
页码:901 / 903
页数:3
相关论文
共 46 条
  • [41] Measures of Adult Systemic Lupus Erythematosus Updated Version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI)
    Romero-Diaz, Juanita
    Isenberg, David
    Ramsey-Goldman, Rosalind
    ARTHRITIS CARE & RESEARCH, 2011, 63 : S37 - S46
  • [42] Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials.
    Han, Chenglong
    Keystone, E.
    Fleischmann, Roy
    Smolen, Josef S.
    Emery, Paul
    Genovese, Mark C.
    Doyle, Mittie K.
    Hsia, Elizabeth C.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S35 - S36
  • [43] VALIDATION OF REMISSION OF RHEUMATOID ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAISNT RHEUMATISM: ANALYSIS BASED ON PATIENT REPORTED OUTCOMES FROM 3 PHASE III CLINICAL TRIALS OF GOLIMUMAB
    Han, C.
    Keystone, E.
    Fleischmann, R.
    Smolen, J. S.
    Emery, P.
    Genovese, M.
    Doyle, M.
    Hsia, E.
    VALUE IN HEALTH, 2012, 15 (04) : A43 - A43
  • [44] Disease activity, interferon-β-1b therapy and neuropsychological assessment in 50 relapsing-remitting multiple sclerosis patients:: preliminary results of a 2-year ongoing study
    Morra, VB
    Florio, C
    Scarano, V
    Vivo, R
    Lanzillo, R
    Muto, M
    Pristner, A
    Coppola, G
    Salvatore, E
    Pagano, A
    Schiavone, V
    Quarantelli, M
    Orefice, G
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S123 - S123
  • [45] VALIDATION OF REMISSION OF RHEUMATOID ARTHRITIS BY TRADITIONAL DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAINST RHEUMATISM: ANALYSIS BASED ON PATIENT-REPORTED OUTCOMES ANALYSED FROM THREE PHASE III GOLIMUMAB CLINICAL TRIALS
    Han, Chenglong
    Keystone, Edward C.
    Fleischmann, Roy
    Smolen, Josef
    Emery, Paul
    Genovese, Mark
    Doyle, Mittie
    Hsia, Elizabeth C.
    RHEUMATOLOGY, 2013, 52 : 83 - 83
  • [46] Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Analysis Based on Patient Reported Outcomes Analyzed from 3 Phase III Golimumab Clinical Trials of Golimumab
    Keystone, Edward
    Han, Chenglong
    Fleischmann, Roy
    Smolen, Josef
    Emery, Paul
    Genovese, Mark
    Doyle, Mittie
    Hsia, Elizabeth
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 968 - 969